DK1268530T3 - Hepatitis B-kerneantigen-fusionsproteiner - Google Patents
Hepatitis B-kerneantigen-fusionsproteinerInfo
- Publication number
- DK1268530T3 DK1268530T3 DK01919645T DK01919645T DK1268530T3 DK 1268530 T3 DK1268530 T3 DK 1268530T3 DK 01919645 T DK01919645 T DK 01919645T DK 01919645 T DK01919645 T DK 01919645T DK 1268530 T3 DK1268530 T3 DK 1268530T3
- Authority
- DK
- Denmark
- Prior art keywords
- particles
- loop
- hbcag
- sequences
- core
- Prior art date
Links
- 102000019040 Nuclear Antigens Human genes 0.000 title 1
- 108010051791 Nuclear Antigens Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 208000002672 hepatitis B Diseases 0.000 title 1
- 101710132601 Capsid protein Proteins 0.000 abstract 7
- 239000002245 particle Substances 0.000 abstract 6
- 239000000539 dimer Substances 0.000 abstract 2
- 230000037431 insertion Effects 0.000 abstract 2
- 238000003780 insertion Methods 0.000 abstract 2
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00107118 | 2000-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1268530T3 true DK1268530T3 (da) | 2006-11-13 |
Family
ID=8168351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01919645T DK1268530T3 (da) | 2000-04-07 | 2001-04-09 | Hepatitis B-kerneantigen-fusionsproteiner |
Country Status (18)
Country | Link |
---|---|
US (1) | US7270821B2 (da) |
EP (1) | EP1268530B1 (da) |
JP (1) | JP4713809B2 (da) |
KR (1) | KR100808313B1 (da) |
CN (1) | CN100360556C (da) |
AP (1) | AP1836A (da) |
AT (1) | ATE336502T1 (da) |
AU (1) | AU784345B2 (da) |
BR (1) | BR0109919A (da) |
CA (1) | CA2405438C (da) |
DE (1) | DE60122300T2 (da) |
DK (1) | DK1268530T3 (da) |
EA (1) | EA200201077A1 (da) |
ES (1) | ES2269371T3 (da) |
MX (1) | MXPA02009895A (da) |
PT (1) | PT1268530E (da) |
WO (1) | WO2001077158A1 (da) |
ZA (1) | ZA200208967B (da) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001027281A1 (en) * | 1999-10-08 | 2001-04-19 | Celltech Pharma Europe Limited | Designing immunogens |
US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
JP4516748B2 (ja) | 2001-09-14 | 2010-08-04 | サイトス バイオテクノロジー アーゲー | ウィルス様粒子中への免疫賦活物質のパッケージ化:調製法および使用法 |
KR100465643B1 (ko) * | 2001-09-28 | 2005-01-13 | (주) 에이프로젠 | 비형 간염 바이러스 프리에쓰1 항원 유래의 에피토프 태그및 이에 대한 항체를 이용한 폴리펩티드의 검출 및 정제방법 |
US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
BR0213117A (pt) | 2001-10-05 | 2004-09-21 | Cytos Biotechnology Ag | Conjugados peptìdeo angiotensina-veìculo e seus usos |
NZ537003A (en) | 2002-07-18 | 2008-03-28 | Cytos Biotechnology Ag | Hapten-carrier conjugates comprising virus like particles and uses thereof |
SI1524994T1 (sl) | 2002-07-19 | 2011-08-31 | Cytos Biotechnology Ag | Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe |
CA2517675A1 (en) | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
CN100537762C (zh) * | 2004-06-24 | 2009-09-09 | 中国人民解放军军事医学科学院野战输血研究所 | 一种嵌合型病毒样颗粒疫苗载体蛋白及其制备方法与应用 |
KR100687653B1 (ko) * | 2005-05-13 | 2007-02-27 | 유기현 | 스타-델타 결선용 전자개폐기의 제어방법 |
EP2185195A2 (en) | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen platform |
US20090214593A1 (en) * | 2007-08-16 | 2009-08-27 | Tripep Ab | Immunogen platform |
PE20142330A1 (es) | 2008-12-09 | 2015-01-14 | Pfizer Vaccines Llc | Vacuna de peptido ch3 de ige |
WO2011013034A1 (en) | 2009-07-30 | 2011-02-03 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
CN104548089B (zh) | 2009-09-03 | 2017-09-26 | 辉瑞疫苗有限责任公司 | Pcsk9疫苗 |
GB0918679D0 (en) * | 2009-10-23 | 2009-12-09 | Iqur Ltd | Influenza vaccine |
JP6199036B2 (ja) | 2010-03-16 | 2017-09-20 | バイオエヌテック アーゲーBioNTech AG | 自己タンパク質に対する体液性免疫応答に関わる腫瘍ワクチン接種 |
WO2011154878A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
EP2680883B1 (en) | 2011-03-02 | 2018-09-05 | Pfizer Inc | Pcsk9 vaccine |
CN102199217B (zh) * | 2011-04-01 | 2013-03-27 | 中国人民解放军第三军医大学 | 乙型肝炎病毒多表位融合蛋白及其制备方法和应用 |
CN103796673A (zh) | 2011-04-15 | 2014-05-14 | 国立大学法人大阪大学 | Dna疫苗 |
EP2891497B1 (en) * | 2012-08-31 | 2020-07-01 | Osaka University | Dna vaccine containing vegf-specific epitope and/or angiopoietin-2-specific epitope |
KR102237130B1 (ko) * | 2012-12-11 | 2021-04-08 | 오시벡스 에스에이에스 | 향상된 특성을 갖는 변형된 코일드 코일 유형 단백질 |
CA2914555A1 (en) * | 2013-06-06 | 2014-12-11 | David J Rowlands | Single domain antibody display |
CN104341506A (zh) * | 2013-07-30 | 2015-02-11 | 复旦大学 | 一种重组融合蛋白及其用途 |
US10279019B2 (en) | 2014-02-11 | 2019-05-07 | Stc.Unm | PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same |
GB201402890D0 (en) * | 2014-02-18 | 2014-04-02 | Iqur Ltd | Vaccines based on hepatitis B Core antigens |
GB201421692D0 (en) * | 2014-12-05 | 2015-01-21 | Iquar Ltd | Vaccines based on hepatitis B core antigens |
GB201505041D0 (en) * | 2015-03-25 | 2015-05-06 | Iqur Ltd | Vaccines based on hepatitis B core antigens |
BR112019009221A2 (pt) * | 2016-11-11 | 2019-07-16 | Fraunhofer Usa Inc | proteína de fusão, método para produzir a proteína, composição, partícula semelhante a vírus, método para produzir partículas semelhantes a vírus, e método para induzir uma resposta imunológica em um sujeito |
CN110343707B (zh) * | 2019-05-30 | 2021-06-15 | 中国科学院生物物理研究所 | 基于乙肝核心抗原的hsv分型用蛋白、试剂盒及方法和应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2480780B1 (fr) * | 1980-04-22 | 1985-12-06 | Pasteur Institut | Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn |
JP2514033B2 (ja) * | 1987-05-20 | 1996-07-10 | 財団法人 癌研究会 | B型肝炎ウィルスの複製を可能とする新規な培養細胞 |
NZ235315A (en) * | 1989-09-19 | 1991-09-25 | Wellcome Found | Chimaeric hepadnavirus core antigen proteins and their construction |
US5723129A (en) * | 1991-10-16 | 1998-03-03 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
JPH06279500A (ja) * | 1992-09-30 | 1994-10-04 | Imuno Japan:Kk | HBc融合蛋白粒子およびその製造方法 |
AU2540897A (en) | 1996-03-21 | 1997-10-10 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and compositions of chimeric polypeptides for tumor antigen vaccines |
US20030021804A1 (en) * | 1997-01-21 | 2003-01-30 | Philip Needleman | Immunological process for increasing the hdl cholestrol concentration |
US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
US6180343B1 (en) * | 1998-10-08 | 2001-01-30 | Rigel Pharmaceuticals, Inc. | Green fluorescent protein fusions with random peptides |
WO2001027281A1 (en) * | 1999-10-08 | 2001-04-19 | Celltech Pharma Europe Limited | Designing immunogens |
AU6616301A (en) * | 2000-06-22 | 2002-01-02 | Celltech Pharmaceuticals Ltd | Modification of hepatitis b core antigen |
US7351413B2 (en) * | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
-
2001
- 2001-04-09 DK DK01919645T patent/DK1268530T3/da active
- 2001-04-09 AU AU46706/01A patent/AU784345B2/en not_active Ceased
- 2001-04-09 JP JP2001575628A patent/JP4713809B2/ja not_active Expired - Fee Related
- 2001-04-09 ES ES01919645T patent/ES2269371T3/es not_active Expired - Lifetime
- 2001-04-09 US US10/240,917 patent/US7270821B2/en not_active Expired - Fee Related
- 2001-04-09 AT AT01919645T patent/ATE336502T1/de active
- 2001-04-09 CA CA2405438A patent/CA2405438C/en not_active Expired - Fee Related
- 2001-04-09 PT PT01919645T patent/PT1268530E/pt unknown
- 2001-04-09 WO PCT/GB2001/001607 patent/WO2001077158A1/en active IP Right Grant
- 2001-04-09 CN CNB018106889A patent/CN100360556C/zh not_active Expired - Fee Related
- 2001-04-09 EA EA200201077A patent/EA200201077A1/ru unknown
- 2001-04-09 AP APAP/P/2002/002658A patent/AP1836A/en active
- 2001-04-09 BR BR0109919-1A patent/BR0109919A/pt not_active IP Right Cessation
- 2001-04-09 DE DE60122300T patent/DE60122300T2/de not_active Expired - Lifetime
- 2001-04-09 EP EP01919645A patent/EP1268530B1/en not_active Expired - Lifetime
- 2001-04-09 KR KR1020027013451A patent/KR100808313B1/ko not_active IP Right Cessation
- 2001-04-09 MX MXPA02009895A patent/MXPA02009895A/es active IP Right Grant
-
2002
- 2002-11-05 ZA ZA200208967A patent/ZA200208967B/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE60122300T2 (de) | 2007-08-30 |
CA2405438A1 (en) | 2001-10-18 |
CA2405438C (en) | 2011-07-12 |
US7270821B2 (en) | 2007-09-18 |
US20040223965A1 (en) | 2004-11-11 |
AU4670601A (en) | 2001-10-23 |
ZA200208967B (en) | 2003-10-08 |
CN1441807A (zh) | 2003-09-10 |
JP4713809B2 (ja) | 2011-06-29 |
EP1268530A1 (en) | 2003-01-02 |
WO2001077158A1 (en) | 2001-10-18 |
ES2269371T3 (es) | 2007-04-01 |
EP1268530B1 (en) | 2006-08-16 |
MXPA02009895A (es) | 2004-09-06 |
EA200201077A1 (ru) | 2003-04-24 |
AU784345B2 (en) | 2006-03-16 |
ATE336502T1 (de) | 2006-09-15 |
PT1268530E (pt) | 2006-12-29 |
JP2003530123A (ja) | 2003-10-14 |
BR0109919A (pt) | 2003-03-11 |
KR100808313B1 (ko) | 2008-02-27 |
KR20030009429A (ko) | 2003-01-29 |
CN100360556C (zh) | 2008-01-09 |
AP1836A (en) | 2008-03-14 |
DE60122300D1 (de) | 2006-09-28 |
AP2002002658A0 (en) | 2002-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1268530T3 (da) | Hepatitis B-kerneantigen-fusionsproteiner | |
Netter et al. | Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes | |
Singh et al. | A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice | |
EA200100619A1 (ru) | Коровые антигенные частицы hbv с множественными иммуногенными компонентами, связанными посредством пептидных лигандов | |
DK1294893T3 (da) | Modifikation af hepatitis B-kerneantigen | |
DK0755259T3 (da) | Kimære-cDNA-kloner af virussen for den infektiöse GUMBORO-syge, ekspressionsprodukter heraf og vacciner baseret derpå | |
CY1111831T1 (el) | Παραγωγα ογκο-συναφους αντιγονου απο την οικογενεια mage και αλληλουχιες νουκλεϊνικου οξεος που κωδικοποιουν αυτα, που χρησιμοποιουνται για την παρασκευη πρωτεϊνων συντηξης και συνθεσεων για εμβολιασμο | |
DE69111801T2 (de) | Vakzin gegen hepatitis b. | |
Wismans et al. | Is booster injection with hepatitis B vaccine necessary in healthy responders?: A study of the immune response | |
EA200300129A1 (ru) | Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах | |
GB9401987D0 (en) | Modified nucleic acid | |
EP1013757A3 (en) | Attenuated forms of bovine viral diarrhea virus | |
CN1874787B (zh) | 预防/治疗hbv感染和hbv介导疾病的组合物 | |
Murray | Application of recombinant DNA techniques in the development of viral vaccines | |
MXPA02012593A (es) | Particulas de tipo virus del virus de la diarrea viral bovina. | |
KR920002629A (ko) | B형 간염 코어 항원의 아미노산 잔기 서열 | |
Ellis et al. | Recombinant hepatitis B vaccines | |
AU583306B2 (en) | Triply cloned hepatitis a live attenuated virus | |
Iwarson | New approaches to hepatitis A and B vaccines | |
CA1292690C (en) | Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic sequentially homologous peptide | |
YU45292A (sh) | Različiti površinski proteini hepatitis b virusa koji obrazuju čestice | |
Michel | DNA-mediated immunization: prospects for hepatitis B vaccination | |
FR2760458B1 (fr) | Peptide structural antigenique, composes antigenique et immunogene et utilisations dans la detection, la prevention et le traitement d'une infection par le vhc | |
DE69814884D1 (de) | Hepatitis b virale polypeptide | |
JP2001517447A5 (da) |